S5192
SB 222200
≥98% (HPLC), solid
别名:
(S)-3-Methyl-2-phenyl-N-(1-phenylpropyl)-4-quinolinecarboxamide
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C26H24N2O
化学文摘社编号:
分子量:
380.48
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
assay
≥98% (HPLC)
form
solid
color
light yellow
solubility
DMSO: soluble ~28 mg/mL, H2O: insoluble
originator
GlaxoSmithKline
storage temp.
2-8°C
SMILES string
CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c3ccccc3)c4ccccc4
InChI
1S/C26H24N2O/c1-3-22(19-12-6-4-7-13-19)28-26(29)24-18(2)25(20-14-8-5-9-15-20)27-23-17-11-10-16-21(23)24/h4-17,22H,3H2,1-2H3,(H,28,29)/t22-/m0/s1
InChI key
MQNYRKWJSMQECI-QFIPXVFZSA-N
Gene Information
human ... TACR2(6865), TACR3(6870)
Application
The pharmacodynamics profile of SB 222200 enables its use as a tool to study physiological and pathophysiological roles of NK-3 receptor in CNS-modulated behaviors.
Biochem/physiol Actions
Non-peptide NK3 tachykinin receptor antagonist.
SB 222200 is a 2-phenyl-4-quinolinecarboxamides and a selective, reversible and competitive antagonist of human NK-3 receptor that effectively crosses the blood-brain barrier. It inhibits the NK-3 receptor-induced miosis or pupil constriction in conscious rabbits.1,2
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from GlaxoSmithKline
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)